HER2CLIMB: New triplet regimen effective, safe, and well tolerated
Key Takeaways
A triplet regimen that combines tucatinib, trastuzumab, and capecitabine is effective in patients with advanced HER2-positive metastatic breast cancer refractory to standard-of-care regimens.
In the HER2CLIMB study, Rashmi Murthy, MD, MD Anderson Cancer Center, Houston, TX, and colleagues studied this triplet regimen and found that it reduced the risk of death by one-third in patients with and without brain metastases. The addition of tucatinib also reduced the risk of progression or death by one-half in all patients and almost doubled objective response rates.
Tucatinib is an investigational agent that is administered orally and is highly selective for HER2, with minimal inhibition of epidermal growth factor receptor. As such, it may have a favorable toxicity profile, without any compromise in efficacy.
These results were shared at SABCS 2019.
ecancer aims to raise the standards of care for cancer patients across the world through education. Visit ecancer.org to find how we can support your education through our high-quality and free resources.
